Point72 Asset Management L.P. Has $48.32 Million Stock Position in Natera, Inc. (NASDAQ:NTRA)

Point72 Asset Management L.P. decreased its stake in Natera, Inc. (NASDAQ:NTRA - Free Report) by 56.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 305,243 shares of the medical research company's stock after selling 391,799 shares during the period. Point72 Asset Management L.P. owned approximately 0.23% of Natera worth $48,320,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of NTRA. Smartleaf Asset Management LLC raised its holdings in shares of Natera by 50.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company's stock worth $104,000 after purchasing an additional 220 shares during the period. SeaBridge Investment Advisors LLC acquired a new position in shares of Natera in the 4th quarter worth $2,894,000. SYM FINANCIAL Corp purchased a new stake in shares of Natera in the 4th quarter valued at approximately $256,000. KBC Group NV boosted its position in Natera by 753.8% during the 4th quarter. KBC Group NV now owns 27,551 shares of the medical research company's stock worth $4,361,000 after acquiring an additional 24,324 shares during the period. Finally, Steward Partners Investment Advisory LLC grew its stake in Natera by 1,328.0% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company's stock valued at $57,000 after purchasing an additional 332 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on NTRA shares. Canaccord Genuity Group reiterated a "buy" rating and issued a $180.00 target price on shares of Natera in a report on Wednesday, February 26th. Piper Sandler upped their price target on Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a research report on Thursday. UBS Group lifted their target price on shares of Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Robert W. Baird raised their price objective on shares of Natera from $183.00 to $188.00 and gave the company an "outperform" rating in a research report on Friday, February 28th. Finally, Morgan Stanley upped their target price on shares of Natera from $176.00 to $185.00 and gave the company an "overweight" rating in a research report on Wednesday, March 5th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $182.12.

Insider Activity

In related news, insider Solomon Moshkevich sold 6,000 shares of Natera stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $143.29, for a total transaction of $859,740.00. Following the completion of the sale, the insider now owns 143,768 shares of the company's stock, valued at approximately $20,600,516.72. The trade was a 4.01% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Steven Leonard Chapman sold 87,272 shares of Natera stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80. Following the sale, the chief executive officer now directly owns 203,354 shares of the company's stock, valued at approximately $29,160,963.60. The trade was a 30.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 152,436 shares of company stock valued at $22,019,079. 7.60% of the stock is owned by company insiders.

Natera Stock Up 0.4%

Shares of Natera stock traded up $0.68 during trading on Monday, reaching $153.27. The stock had a trading volume of 752,259 shares, compared to its average volume of 1,385,783. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $20.93 billion, a price-to-earnings ratio of -87.09 and a beta of 1.79. Natera, Inc. has a 52 week low of $92.14 and a 52 week high of $183.00. The stock has a fifty day moving average price of $148.89 and a two-hundred day moving average price of $157.17.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.09. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. During the same quarter last year, the company earned ($0.56) EPS. Natera's revenue for the quarter was up 36.5% compared to the same quarter last year. Sell-side analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.